The Effect of Dantonic™ on Diabetes and Its Serious Complications

Chapter

Abstract

With improvements in living standards and the spread of Western lifestyle, the prevalence of diabetes has been growing. Epidemiological studies have proven that type 2 diabetes has increased year by year, which is also related to the aging of the population. Therefore, diabetes has become the third largest noncommunicable disease, following cardiovascular diseases and cancer. In 1998, according to the World Health Report of the WHO, it was estimated that there were more than 143 million diabetes patients in the world, and the figure was expected to increase to 300 million by 2025. In recent years, the conception of the metabolic syndrome in the prevention and treatment of coronary heart disease has integrated a variety of risk factors, including the increase of fasting blood glucose, insulin resistance, and impaired glucose tolerance, which are closely related to the glucose metabolism of the body. Diabetes is also one of the most important risk factors for coronary heart disease , and coronary heart disease is the most common complication of diabetes .

Keywords

Diabetic Nephropathy DRDiabetic Retinopathy Proliferative Diabetic Retinopathy Calcium Dobesilate Visual Field Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hui D, Ming J, Wei Y, et al. J Tradit Chin Ophthalmol. 2005;15(2):72.Google Scholar
  2. 2.
    Bin W. Chin J Gen Med. 2004;3(11):58.Google Scholar
  3. 3.
    Lingzhi B, Guang Y, Haibin W. Hebei J Tradit Chin Med. 2006;28(4):304.Google Scholar
  4. 4.
    Yuebin Z, Ruihua W, Guoqing W. Chin J Integr Tradit West Nephrol. 2007;8(2):112.Google Scholar
  5. 5.
    Yujie G. Med J Chin People’s Health. 2007;19(3):117.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Guoguang Zhu
    • 1
  • Renshu Li
    • 1
  • Ying Zhao
    • 1
  • Ruizhi Luo
    • 1
  1. 1.The European Federation of Pharmaceutical SocietyStockholmSweden

Personalised recommendations